

soliton

Advanced Shockwave Technology



Overview summary

Soliton has created a device used in conjunction with existing lasers to accelerate tattoo fading


As seen in our own clinical trials, we achieved results with our RAP device in 2-3 visits that may normally require 10 or more office visits with a stand-alone laser

Human trials for submission to the FDA are complete and Soliton believes our FDA submission will be cleared by mid 2019


Limited distribution is planned to key opinion leaders in the second half of 2019, followed by broad market launch in 2020

Potential non-invasive cellulite treatment and acceleration of existing methods of fat removal appear possible as additional indications

According to Market Research Future, the global market for tattoo removal is projected to be over \$4 billion by 2023.



44 million Americans want some form of tattoo removal



So, why isn't this already a billion dollar business?



* As demonstrated in our own proprietary market research conducted by iResearch in conjunction with The Phillips Agency.


** The Harris Poll of 2,225 U.S. adults surveyed online from October 14-19, 2015.

Current standard of care (laser removal) presents huge barriers

A complete removal for this patient
could mean repeating this visit 10 or
more times over the next 1 to 2
years (December 2012 Archives of Dermatology)

Reducing this timeline will truly
change the process


What limits a laser's effectiveness?



Archives of Dermatology, Volume 148
(No. 12), December 2012



Two Major Causes of Laser Shielding



Each office visit is limited to just one laser treatment because these dermal vacuoles can take days to resolve*

*based on biopsies performed days post treatment in our own labs

Soliton's Rapid Acoustic Pulse (RAP) technology changes all this by removing vacuoles and dispersing particles

Electro-hydraulics (arc plasma in saline)


- utilizes 3000 volts at 3000 amps
- creates shockwaves from 2 to 6 MPa @ 100 Hz

Electronic wave shaping

- enables very high repetition rate
- reduces unwanted frequencies that cause heat and pain

Custom designed reflector

- eliminates cavitation, heat, pain
- non-focused, slightly diverging waves



8 patent families filed

Worldwide exclusive license from MD Anderson

60601 Electrical Safety certified; 2 MOPP/MOOP

IRB “non-significant risk” established

RAP device enables multiple laser treatments in one visit

Our most recent clinical trials:

- demonstrated that Soliton's RAP device enables multiple laser passes in a single office visit
- achieved tattoo fading results with our RAP device in 2-3 visits that may normally require 10 or more office visits with a stand-alone laser

We believe RAP may have the following potential benefits:

As little as 2-3 office visits vs. 10 or more office visits

Clinical trial participants generally experienced little to no pain.

Less risk of scarring or ghosting


Overall better outcome

Lower cost to patient

Higher revenue opportunity for physician

Makes an average Q-switch laser perform better than a \$250k Pico-switched laser

Here's how we believe Soliton RAP enables multiple laser passes



RAP removes the vacuoles created by the first laser pass and helps disperse particles


With vacuoles removed and particles disbursed, a second laser treatment is possible

The next laser pass is much more effective; can be repeated multiple times

Remarkable clinical results


After approximately 3 office visits, the Soliton RAP delivered 75% or greater fading in 100% of patients*

Soliton outperformed “laser-only” 100%* of the time



*Results presented from the Company's 2017 clinical trial. Fading percentages were determined by a panel of unaffiliated doctors who reviewed the patient results and graded fading.


Leg Vine - Complete removal of treated
ink after 3 treatments



Before

After 3 Treatments

Compared with historical controls, Soliton RAP changes the removal timeline




A Soliton laser treatment machine is shown in a clinical setting. The machine has a teal handle and a white control panel with the Soliton logo. A teal cable is connected to the machine. In the background, there is a white cabinet with several glass jars on top. A black treatment bed is visible in the foreground.

Revenue Potential

**Initial opportunity:
Global market projected
to be over \$4B by 2023***


* Per Tattoo Removal Market Research Report
published by marketresearchfuture.com

Device and revenue strategy




Sell or lease
consoles

***“razor and blade”** recurring revenue model*



Hand piece contains
replaceable cartridge



Replaceable consumable
cartridge good for
one patient visit

Management and Directors

All life science veterans

Multiple device clearances

Multiple national and international aesthetic device launches

Wally Klemp
Exec. Chairman
#1 INC 500
Startup to \$.5 billion
revenues



Chris Capelli, MD
President/CSO
MIT Engineer
Co-inventor of early
Dexcom Technology



Brad Hauser
Independent Dir.
Allergan - CoolSculpt
GM (Previously Zeltiq)
Laser Industry Veteran



Lori Bisson
EVP/CFO
Public Co veteran
Ex-Big 4 Accounting



Danika Harrison
Independent Dir.
Zeltiq Head of Marketing
Aesthetics Marketing
Expert



Joe Tanner
COO
Multiple Med Devices
Contract Electronics
Executive



Jon Foster
Independent Dir.
Delloitte/
Public Life Science
CFO










Science Advisory Board

High profile Key
Opinion Leaders

Strong podium
presence

Respected, published
researchers

* Also members of the CoolSculpting
Medical Advisory Board



RAP has potential for cellulite reduction

Lack of collagen production leads to weakening of skin structure; considered a primary cause of cellulite

Animal studies show Soliton RAP may stimulate new collagen production

Human clinical studies using RAP to reduce cellulite have been initiated this year



**90% of women experience cellulite
according to Scientific American**

Accelerating fat removal techniques

Current fat reduction techniques are limited to a 20% to 30% reduction in subcutaneous fat*

Soliton RAP has been shown to destroy fat cells in animal testing

Collaborative clinical testing in humans is under way with a multibillion-dollar global aesthetics company to test RAP's ability to accelerate current fat removal technology



* as indicated in CoolSculpting® clinical results

Legal Disclaimer

We make statements herein that are considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend for these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement herein for purposes of complying with those safe harbor provisions. Similar statements are made in the Offering Circulars or offering memoranda of Soliton, Inc. (“Soliton”). These forward-looking statements reflect, as applicable, our or Soliton’s current views about plans, intentions, expectations, strategies and prospects, which are based on the information currently available to Soliton or us and on assumptions Soliton or we have made. Although Soliton or we believe that such plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, Soliton or we can give no assurance that such plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond Soliton’s or our control. For further discussion of the factors that could affect outcomes, please refer to the risk factors set forth in the “Risk Factors” sections of the Final Offering Circular of Soliton’s Regulation A+ Offering. Soliton or we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation has been prepared by Soliton for informational purposes and does not constitute an offer to sell or the solicitation of an offer to purchase securities. Any such offer will be made solely by means of the offering circular contained in a qualified offering statement. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become qualified. The information contained herein may not be used in connection with an offer of solicitation by anyone in any jurisdiction in which such offer or solicitation is not qualified or any person to whom it is unlawful to make such offer or solicitation.

An investment in Soliton has a high degree of risk including the lack of a listed market for its securities, as well as other risks common to Regulation A+ investments generally, including, but not limited to, a small equity market capitalization and lack of public float, which may impair the liquidity of these investments. Soliton can make no assurances about the success of its products, licensing or marketing efforts, or their ability to qualify for a listing on a national, or any other, securities exchange; consequently, investors in Soliton may lose some or all of their investments.

Soliton is accepting reservations for an Offering under Tier II of Regulation A. No money or other consideration is being solicited, and if sent in response, it will not be accepted. No sales of securities will be made or commitment to purchase accepted until qualification of the offering statement by the U.S. Securities and Exchange Commission and approval of any other required government or regulatory agency. A reservation is non-binding and involves no obligation or commitment of any kind. No offer to buy securities can be accepted and no part of the purchase price can be received without an Offering Statement that has been qualified by the U.S. Securities and Exchange Commission. A Preliminary Offering Circular that forms a part of the Offering Statement has been filed with the U.S. Securities and Exchange Commission, a copy of which may be obtained from Soliton: <https://www.flashfunders.com/soliton>.

The RAP device will need to receive clearance from the Food and Drug Administration, or FDA, in order to be marketed in the United States. Soliton expects to submit its filing for premarket clearance approval with the FDA in the third quarter of 2018. The RAP device is dependent upon regulatory approval and will be subject to ongoing regulatory review, and any failure to secure clearance or comply with continuing regulation by the FDA or other regulatory bodies could prevent the RAP device from entering the market.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved or passed upon the accuracy or adequacy of this presentation or of the offering circular. Before investing, please carefully read the offering circular contained in the offering statement, which may be found at:

[LINK]

Disclaimer

All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements.

Soliton is accepting reservations for an Offering under Tier II of Regulation A. No money or other consideration is being solicited, and if sent in response, it will not be accepted. No sales of securities will be made or commitment to purchase accepted until qualification of the offering statement by the Securities and Exchange Commission (the “Commission”) and approval of any other required government or regulatory agency. A reservation is non-binding and involves no obligation or commitment of any kind. No offer to buy securities can be accepted and no part of the purchase price can be received without an Offering Statement that has been qualified by the Commission. A Preliminary Offering Circular that forms a part of the Offering Statement has been filed with the Commission, a copy of which may be obtained from Soliton: <https://www.flashfunders.com/soliton>